12.12.2016 • TopicsSanofiJochen Maas

Experts Statements: Prof. Jochen Maas, Sanofi-Aventis Deutschland

Prof. Jochen Maas, Head R&D FF, Sanofi-Aventis Deutschland
Prof. Jochen Maas, Head R&D FF, Sanofi-Aventis Deutschland

Despite tremendous challenges facing the pharmaceutical industry, it continues with its commitment to innovation and the discovery of novel drugs to address unmet medical needs. Indeed, medicinal chemists face a challenge of their own. Trying to survive in a changing environment where pharma is focusing on biologics drug candidates will require chemists to adapt.

CHEManager International asked R&D experts of chemical and pharmaceutical companies to elaborate on their research strategy and share their opinion with our readers. In detail, we interviewed professionals ranging from CEOs to heads of R&D and process development about:

 

The crucial success factors in chemical and pharmaceutical research.

Prof. Jochen Maas: Œ The crucial factor in chemical research will be people — well-educated and with the right empathy and motivation for research. Those people have to be brought together independently of their organizations — academia, industry or biotech. And this requires new and innovative ideas of collaboration, which have already started to be implemented.

 

The crucial factor … will be
people — well-educated and
with the right empathy and
motivation for research.

Prof. Jochen Maas,
Head R&D FF,
Sanofi-Aventis Deutschland

 

The role of information technology tools in developing reaction routes and processes.

Prof. Jochen Maas: The role of software tools to predict and develop reaction routes and processes for given target molecules depends on the research area: A lot of processes already can be predicted quite accurately by in silico approaches — e.g., absorption. Other areas like metabolism will require much more effort to achieve a similar level.

Challenges and changes affecting the work of R&D chemists in the future.

Prof. Jochen Maas:  R&D chemists will have to be extremely flexible in the future: At least industry preferences for specific modalities — like small molecules, peptides, proteins, oligonucleotides — will probably change much more rapidly than in the past.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.